What is Kymera Therapeutics Inc (KYMR) stock price today?

Kymera Therapeutics Inc (KYMR) currently trades at $81.51 per share. The stock has a market capitalization of $6.65B and a P/E ratio of —x.

Is KYMR stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Kymera Therapeutics Inc has a Smart Value Score of 24/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 3/9 and Altman Z-Score is 1.97.

What is Kymera Therapeutics Inc's revenue and earnings?

Kymera Therapeutics Inc has trailing twelve-month (TTM) revenue of $39.21M with profit margins of 0.00%. Earnings per share (EPS) is $-3.69.

Is Kymera Therapeutics Inc financially healthy?

Kymera Therapeutics Inc's Piotroski F-Score is 3/9 (weak financial health). The Altman Z-Score of 1.97 places it in the grey zone.

KYMR

Kymera Therapeutics Inc

NASDAQ: KYMR · HEALTHCARE · BIOTECHNOLOGY

$81.51

-2.79% today

Updated 2026-04-29

Market cap

$6.65B

P/E ratio

—

P/S ratio

169.71x

EPS (TTM)

$-3.69

Dividend yield

—

52W range

$28 – $103

Volume

0.7M

Market cap

$6.65B

P/E ratio

—

P/S ratio

169.71x

EPS (TTM)

$-3.69

Dividend yield

—

52W range

$28 – $103

Volume

0.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

2.7

Growth

7.5

Quality

B+

2.5

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

2.0

Altman Z-Score

Grey zone

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$119.14

+46.17%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

5 Strong Buy17 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.09x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-66.85M

- Revenue declining -61.20% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$46.83M	$78.59M	$47.07M	$39.20M	$39.21M
Net income	$-154.81M	$-146.96M	$-223.86M	$-311.40M	$-87.03M
EPS	—	—	—	—	$-3.69
Free cash flow	$-155.92M	$-137.31M	$-207.34M	$-234.34M	$-66.85M
Profit margin	-330.60%	-186.99%	-475.57%	-794.39%	—

Recent insider activity

Date	Insider	Type	Shares	Price
2026-04-15	CHADWICK, JEREMY G	Sale	1,300	—
2026-04-15	CHADWICK, JEREMY G	Sale	1,300	$90.00
2026-04-15	BOOTH, BRUCE	Sale	2,200	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
KYMR	$6.65B	24	2.7	2.5	5.0	7.5	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Kymera Therapeutics Inc trades at $81.51. Our Smart Value Score of 24/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.97, it sits in the grey zone. TTM revenue stands at $39.21M.

Frequently asked questions

What is Kymera Therapeutics Inc's stock price?

Kymera Therapeutics Inc (KYMR) trades at $81.51.

Is Kymera Therapeutics Inc overvalued?

Smart Value Score 24/100 (Grade F, Strong Sell).

What is the price target of Kymera Therapeutics Inc (KYMR)?

The analyst target price is $119.14, representing +46.2% upside from the current price of $81.51.

What is Kymera Therapeutics Inc's revenue?

TTM revenue is $39.21M.

Piotroski F-Score?

3/9 — weak financial health.

Altman Z-Score?

1.97 — grey zone.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

www.kymeratx.com

Quick metrics

P/S ratio169.71x

ROE-25.80%

Beta2.29

50D MA$84.62

200D MA$66.84

Shares out0.08B

Float0.05B

Short ratio—

Avg volume0.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

KYMR vs LLY →KYMR vs JNJ →KYMR vs ABBV →Stock screener →